The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

about

The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis

Item

http://www.wikidata.org/entity/Q57412755

description

scientific article published on 26 May 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в травні 2018

@uk

name

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@en

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@nl

type

Item

label

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@en

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@nl

prefLabel

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@en

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@nl

P1476

The effect of basal-bolus ther ...... diabetes: a post hoc analysis

@en

P2093

A Gorst-Rasmussen

http://www.w3.org/2001/XMLSchema#string

A Liebl

http://www.w3.org/2001/XMLSchema#string

K Buchholtz

http://www.w3.org/2001/XMLSchema#string

P Raskin

http://www.w3.org/2001/XMLSchema#string

T R Pieber

http://www.w3.org/2001/XMLSchema#string

P2860

Serum 1,5-anhydroglucitol (GlycoMark ): a short-term glycemic marker.

Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay.

Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.

1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes.

1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions.

Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.

Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients.

Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.

Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3).

P304

1273-1278

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DME.13693

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simon Heller

K Bowering

P577

2018-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29802636

http://www.w3.org/2001/XMLSchema#string

P921

endocrinology

type-2 diabetes

P932

6099439

http://www.w3.org/2001/XMLSchema#string